Innovating Works

Enhanced-DDS

Financiado
An enhanced drug delivery system for brain cancer treatment which will be tested...
An enhanced drug delivery system for brain cancer treatment which will be tested by human cell-based 3D in vitro microfluidic system Cancer treatment by current clinical methods has many side effects, which result from the non-specificity of these methods. Moreover, treatment of some cancers, such as brain tumors, is extremely difficult because the brain barrie... Cancer treatment by current clinical methods has many side effects, which result from the non-specificity of these methods. Moreover, treatment of some cancers, such as brain tumors, is extremely difficult because the brain barriers (blood-brain barrier (BBB) and blood tumor barrier (BTB)) prevents more than 98% of drugs from entering the brain. The use of stimuli-responsive nanomaterials for cancer therapy is more efficient than conventional ones due to access to targeting tissues, deep molecular targets, lower side effects, and controlled drug release. Mesoporous silica nanoparticles (MSNs) are widely used nanocarrier for drug delivery due to their unique physicochemical properties. However, the lack of consideration of the economic efficiency of MSNs synthesis, their surface modification methods, and the lack of use of physiologically relevant systems to test the efficacy and safety of MSNs, have caused that an effective and definitive cancer treatment method by MSNs has not been provided so far. In this project we aim to solve these problems and make the use of MSNs for therapeutic approaches realistic. The goal of this project is to develop a biosource-derived stimuli-responsive MSN for combined PDT/ chemotherapy of brain tumors to be evaluated in a physiologically relevant human cell-based 3D in vitro brain tumor microfluidic system. This project will be the first to investigate a combination therapeutic agent based on natural products modified with advanced plasma technology and evaluated in a novel human cell-based 3D microfluidic in vitro system that includes the BBB. Outcomes of this project will enhance the existing knowledge and technologies for MSNs’ synthesis, modification, and their cancer treatment performance evaluation, which will yield high-impact journal publications, as well as potential commercial product in the long term. ver más
30/06/2025
SABANCI UNIVERSITY
148K€
Perfil tecnológico estimado
Duración del proyecto: 26 meses Fecha Inicio: 2023-04-27
Fecha Fin: 2025-06-30

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-27
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 148K€
Líder del proyecto
SABANCI UNIVERSITESI No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5